Skip to content

MBX Biosciences, Inc. MBX Operating Cash Flow

Operating Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$5.33B+220%
Amgen logo
AmgenAMGN
$2.19B+57.4%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$113.98M-118%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
-$36.88M+7.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
-$197.28M+1.0%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$71.91M-17.7%

Other financials

Income statement

See full
Operating income-$27.3M-2.8%
Net income-$23.5M+1.5%
EPS (diluted)-$0.50+29.6%

Balance sheet

See full
Cash & equivalents$45.2M+51.2%
Total debt$555.0K+327%
Total equity$437.8M+85.9%
Total assets$452.7M+84.1%

Cash flow

See full
CapEx$437.0K+1,357%
Free cash flow-$20.6M+9.1%

Valuation

See full
Market cap$2.21B+475%
Enterprise value$2.16B+533%

Returns & leverage

See full
Return on equity-25.7%
Debt / equity0.0×
Current ratio30.8×+7.5×

Where this comes from

Reported directly by MBX Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about MBX Biosciences, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MBX Biosciences, Inc.'s operating cash flow?
MBX Biosciences, Inc. (MBX) reported operating cash flow of -$20.21M in Q1 2026.
How has MBX Biosciences, Inc.'s operating cash flow changed year-over-year?
MBX Biosciences, Inc.'s operating cash flow increased by 10.9% year-over-year, from -$22.68M to -$20.21M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.